GLP1, a processed active peptide of 30aa (chr 2q36-q37) is a potent insulin secretagogue, and plays a major role in the enteroinsular axis, accounting for the finding that plasma insulin levels accompanying oral intake of glucose are greater than those observed when glucose is given intravenously
Glucagon is a member of a multigene family comprising of Secretin, Vasoactive Intestinal Peptide (VIP), Gastric Inhibitory Peptide (GIP) and others like Glicentin and Oxyntomodulin (OXM), which differs from glucagon by C-terminal octapeptide.
The glucagon precursor contains at least 3 intervening sequences that divide the protein-coding portion into 4 regions corresponding to the signal peptide and part of the N-terminal peptide, the remainder of the N-terminal peptide and glucagon, glucagon-like peptide-1 (GLP1), and GLP2.
The GLP 1 & 2 stimulate intestinal growth and up regulate villus height in the small intestine, concomitant with increased crupt cell proliferation and decreased enterocyte apoptosis.
The two GLP's are mainly produced in the A cells of the Islets of Langerhans in response to a drop in blood sugar concentration.
Applications:Suitable for use in Immunohistochemistry.
Other applications not tested.
Recommended Dilutions:Immunohistochemistry (Formalin-fixed paraffin): 1:500 (DAB)Optimal dilutions to be determined by the researcher.
